Enzyme replacement therapy in feline mucopolysaccharidosis I.
Enzyme replacement therapy (ERT) has long been considered an approach to treating lysosomal storage disorders caused by deficiency of lysosomal enzymes. ERT is currently used to treat Gaucher disease and is being developed for several lysosomal storage disorders now that recombinant sources of the enzymes have become available. We have continued development of ERT for mucopolysaccharidosis I (MPS I) using the feline model. Recombinant alpha-L-iduronidase was administered intravenously at low dose (approximately 0.1 mg/kg or 25,000 units/kg) to four cats and high dose (0.5 mg/kg or 125,000 units/kg) to two cats on a weekly basis for 3- or 6-month terms. Clinical examinations showed distinct clearing of corneal clouding in one cat although clinical effects in the others were not evident. Biochemical studies of the cats showed that the enzyme was distributed to a variety of tissues although the liver and spleen contained the highest enzyme activities. Glycosaminoglycan storage was decreased in liver and spleen, and the histologic appearance improved in liver, spleen, and renal cortex. Enzyme was not consistently detected in cerebral cortex, brainstem, or cerebellum and the histologic appearance and ganglioside profiles did not improve. A variety of other tissues showed low variable uptake of enzyme and no distinct improvement. IgG antibodies to alpha-L-iduronidase were observed in five cats with higher titers noted when higher doses were administered. Mild complement activation occurred in three cats. Enzyme replacement therapy was effective in reversing storage in some tissues at the biochemical and histologic level in MPS I cats but an improved tissue distribution and prevention of a significant immune response could make the therapy more effective.
Department of Pediatrics, Division of Medical Genetics, Harbor-UCLA Medical Center, Torrance, California 90502, USA. ekakkis@biomarinpharm.com
E D
ED
Kakkis
E
E
Schuchman
X
X
He
Q
Q
Wan
S
S
Kania
S
S
Wiemelt
C W
CW
Hasson
T
T
O'Malley
M A
MA
Weil
G A
GA
Aguirre
D E
DE
Brown
M E
ME
Haskins
D000818:Animals; D001921:Brain / Q000378:metabolism; D002415:Cats; D006025:Glycosaminoglycans / Q000378:metabolism; D007068:Iduronidase / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000096:biosynthesis; D007262:Infusions, Intravenous; D007672:Kidney Cortex / Q000378:metabolism / Q000648:ultrastructure; D008099:Liver / Q000378:metabolism / Q000648:ultrastructure; D008059:Mucopolysaccharidosis I / Q000188:drug therapy* / Q000473:pathology; D011994:Recombinant Proteins / Q000627:therapeutic use; D013154:Spleen / Q000378:metabolism / Q000648:ultrastructure; D014018:Tissue Distribution
D006025:Glycosaminoglycans; D007074:Immunoglobulin G; D011994:Recombinant Proteins; D007068:Iduronidase